This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

Rise above the complexity with TEZSPIRE^® (tezepelumab)^1-3,6

See full indication

TEZSPIRE significantly reduces exacerbations in a broad population of severe uncontrolled asthma patients aged 12 and over^3-5*

Navigator

Annualised asthma
exacerbation relative risk
reduction vs placebo

TEZSPIRE 0.93 (n=528) vs placebo 2.1 (n=531)
RR=0.44, 95% CI: 0.37-0.53;
P<0.001;

ARR=1.17

PRIMARY ENDPOINT OF NAVIGATOR (PHASE III STUDY): AAER VS PLACEBO OVER 52 WEEKS^†3,4

Primary endpoint also assessed in patients with
baseline bEOS <300 cells/μL

SEE EFFICACY DATA

Pathway

Annualised asthma
exacerbation relative risk
reduction vs placebo

TEZSPIRE 0.2 (n=137) vs placebo 0.72 (n=138),
90% CI: 0.54-0.82; P<0.001;

ARR=0.52

PRIMARY ENDPOINT OF PATHWAY (PHASE IIb STUDY): AAER VS PLACEBO OVER 52 WEEKS^‡4,7

SEE EFFICACY DATA

^*Patients enrolled with no minimum biomarker requirement (blood EOS, IgE, or FENO).¹
^†NAVIGATOR study. All patients received SOC (MD or HD ICS + additional controller).^3,4
^‡PATHWAY study. All patients received SOC (MD or HD ICS + additional controller).^4,7

TEZSPIRE treats across phenotypes and irrespective of key clinical biomarker levels¹

No restrictions across eosinophilic and non-eosinophilic, allergic and non-allergic phenotypes; eosinophils, IgE, and FeNO biomarkers.

FeNO=fractional exhaled nitric oxide; IgE=immunoglobin E; MOA=mode of action.

EXPLORE MOA

TEZSPIRE (tezepelumab) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment¹

AAER=annualised asthma exacerbation rate; ARR=absolute risk reduction; CI=confidence interval; bEOS=blood eosinophils; FeNO=fractional exhaled nitric oxide; HD=high dose; ICS=inhaled corticosteroid; IgE=immunoglobulin E; MD=medium dose; MOA=mode of action; RR=rate ratio; SOC=standard of care.

Tezspire (tezepelumab). Summary of Product Characteristics. 2022. Available at: https://www.medicines.org.uk/emc/product/14064/smpc (last accessed: November 2024).
Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?. Respir Res. 2020;21(1):268.
Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
Menzies-Gow A, Corren J, Bourdin A, et al. Supplementary Appendix. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946.
Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792.
Corren J, Parnes JR, Wang L, et al. Supplementary Appendix. Tezepelumab in Adults with Uncontrolled Asthma N Engl J Med. 2017;377(10):936-946.

GB-62660 | December 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

Rise above the complexity with TEZSPIRE® (tezepelumab)1-3,6

TEZSPIRE significantly reduces exacerbations in a broad population of severe uncontrolled asthma patients aged 12 and over3-5*

Navigator

Annualised asthma exacerbation relative risk reduction vs placebo

ARR=1.17

Pathway

Annualised asthma exacerbation relative risk reduction vs placebo

ARR=0.52

TEZSPIRE treats across phenotypes and irrespective of key clinical biomarker levels1

Abbreviations and References

Rise above the complexity with TEZSPIRE^® (tezepelumab)^1-3,6

TEZSPIRE significantly reduces exacerbations in a broad population of severe uncontrolled asthma patients aged 12 and over^3-5*

Annualised asthma
exacerbation relative risk
reduction vs placebo

Annualised asthma
exacerbation relative risk
reduction vs placebo

TEZSPIRE treats across phenotypes and irrespective of key clinical biomarker levels¹